Committee for Advanced Therapies (CAT)
Minutes of the meeting on 17-19 January 2024

Chair: Ilona Reischl; Vice-Chair: Kieran Breen

Disclaimers
Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, these minutes are a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents
Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).
Table of contents

1. Introduction 5

1.1. Welcome and declarations of interest of members, alternates and experts .......... 5
1.2. Adoption of agenda ........................................................................................................ 5
1.3. Adoption of the minutes ............................................................................................. 5

2. Evaluation of ATMPs 5

2.1. Opinions ...................................................................................................................... 5
2.2. Oral explanations ........................................................................................................ 5
2.3. Day 180 list of outstanding issues ........................................................................... 6
2.4. Day 120 list of questions .......................................................................................... 6
2.5. Day 80 assessment reports ......................................................................................... 6
2.6. Update on ongoing initial applications ...................................................................... 6
2.7. New applications ....................................................................................................... 6
2.7.1. Autologous cartilage-derived articular chondrocytes, in-vitro expanded - EMEA/H/C/0045946
2.8. Withdrawal of initial marketing authorisation application ...................................... 6
2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004 ........................................... 6
2.10. Companion diagnostics ............................................................................................ 6
2.10.1. Initial consultation ................................................................................................. 6
2.10.2. Follow-up consultation ........................................................................................ 6
2.11. Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 .............................................................. 7
2.11.1. Abecma - Idecabtagene vicleucel - Orphan - EMEA/H/C/004662/II/0031 .............. 7
2.11.2. Alofisel - Darvadstrocel - Orphan - EMEA/H/C/004258/II/0047/G ......................... 7
2.11.3. CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/II/0023 ...... 8
2.11.4. Upstaza - Eladocagene exuparvovec - Orphan - EMEA/H/C/005352/II/0013 .......... 8
2.11.5. Upstaza - Eladocagene exuparvovec - Orphan - EMEA/H/C/005352/II/0014/G ........ 8
2.11.6. Tecartus; Yescarta - Axicabtagene ciloleucel; Brexucabtagene autoleucel - Orphan - EMEA/H/C/WS2607 .................................................................................................................. 9
2.11.7. CARVYKTI - ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/II/0021 ....... 9
2.12. Extension applications ............................................................................................ 9

2.13. Other Post-Authorisation Activities ..................................................................... 9
2.13.1. Abecma - Idecabtagene vicleucel - Orphan - EMEA/H/C/004662/MEA/007 ............ 9
2.13.2. Abecma - Idecabtagene vicleucel - Orphan - EMEA/H/C/004662/REC/016.1 .......... 10
2.13.3. Breyanzi - Lisocabtagene maraleucel / Lisocabtagene maraleucel - EMEA/H/C/004731/MEA/007 .......................................................... 10
2.13.4. Breyanzi - Lisocabtagene maraleucel / Lisocabtagene maraleucel - EMEA/H/C/004731/REC/017 ............................................................... 10
2.13.5. CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/ANX/003.1 ......... 11
2.13.6. CARVYKITI - Ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/R/0025 ................. 11
2.13.7. CARVYKITI - Ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/REC/013.1 .......... 11
2.13.8. Kymriah - Tisagenlecleucel - Orphan - EMEA/H/C/004090/ANX/009.7 ..................... 11
2.13.9. Kymriah - Tisagenlecleucel - Orphan - EMEA/H/C/004090/LEG/021.1 ................ 12
2.13.10. Kymriah - Tisagenlecleucel - Orphan - EMEA/H/C/004090/P46/022 ...................... 12
2.13.11. Luxturna - Voretigene neparvovec - Orphan - EMEA/H/C/004451/REC/012 .............. 12
2.13.12. ROCTAVIAN - Valoctocogene roxaparvovec - Orphan - EMEA/H/C/005830/SOB/006 ....... 12
2.13.13. Abecma - idecabtagene vicleucel; Breyanzi - lisocabtagene maraleucel; Carvykti - ciltabtagene autoleucel; Kymriah - tisagenlecleucel; Tecartus - brexucabtagene autoleucel; Yescarta - axicabtagene ciloleucel ................................................................. 13

2.14. GMP and GCP inspections requests .............................................................................. 13

3. Certification of ATMPs

3.1. Opinion ......................................................................................................................... 13
3.2. Day 60 Evaluation Reports ......................................................................................... 13
3.3. New Applications ........................................................................................................ 13

4. Scientific Recommendation on Classification of ATMPs

4.1. New requests – Appointment of CAT Coordinator .................................................. 14
4.1.1. Modified measles vaccine virus .............................................................................. 14
4.2. Day 30 ATMP scientific recommendation ............................................................. 14
4.2.1. Allogeneic expanded natural killer cells ................................................................. 14
4.2.2. Autologous tissue generated in the human body (in vivo) through the foreign body reaction 14
4.2.3. Dendritic cells activated by lysate of circulating tumour cells .............................. 14
4.2.4. Autologous T Lymphocytes engineered with nanoparticles with curcumin incapsulated .... 15
4.3. Day 60 revised scientific recommendation (following list of questions) ............... 15
4.3.1. Spermatogonial stem cells, propagated in vitro .................................................... 15
4.4. Finalisation of procedure ...................................................................................... 15
4.4.1. Allogeneic peripheral blood-derived HSPC, Treg cells and Tcon cells ............... 15
4.5. Follow-up and guidance ........................................................................................ 15

5. Scientific Advice

5.1. New requests - appointment of CAT Rapporteurs ................................................ 16
5.1.1. Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers ....... 16
5.1.2. Scientific advice procedures starting at the next SAWP meeting ....................... 16
5.2. Procedures discussed at SAWP – 1st reports, D40 JRIs, LoIs ................................. 16
5.3. Finalisation of D70 procedures – feedback from the discussion meeting .............. 16
5.4. Final Advice Letters for procedures finalised the previous month ....................... 16

6. Pre-Authorisation Activities

6.1. Paediatric investigation plans .................................................................................. 16
6.2. ITF briefing meetings in the field of ATMPs .......................................................... 17
6.3. Priority Medicines (PRIME) – Eligibility requests ............................................. 17
6.3.1. Month 0 - Start of the procedure ...................................................................... 17
6.3.2. Month 1 – Discussion of eligibility ................................................................. 17
6.3.3. Month 2 – Recommendation of eligibility ...................................................... 17
6.3.4. Ongoing support ............................................................................................. 17

7. Organisational, regulatory and methodological matters ....................................... 17
7.1. Mandate and organisation of the CAT .............................................................. 17
7.1.1. CAT membership ........................................................................................... 17
7.1.2. Vote by proxy ................................................................................................. 18
7.1.3. CAT Strategic Review & Learning meeting (SRLM) under the Belgian presidency – 15-17 May 2024 ...................................................................................................................... 18
7.2. Coordination with EMA Scientific Committees ............................................... 18
7.2.1. BWP/CAT training on AAV based gene therapy ............................................. 18
7.2.2. Update on revamp project: available new templates, ongoing template revision and industry pilot ....................................................................................................................... 18
7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups .... 18
7.4. Coordination with the EU regulatory network .................................................. 19
7.5. Cooperation with international regulators ....................................................... 19
7.6. CAT work plan .................................................................................................. 19
7.6.1. CAT work plan for 2024 ............................................................................... 19
7.6.2. Update on real-world evidence (RWE) studies to support EMA scientific committees ................................................................. 19
7.6.3. Reflection paper on the use of real-world data to generate real-world evidence in non-interventional studies .......................................................... 19
7.6.4. Guideline on quality, non-clinical and clinical requirements for investigational ATMPs in clinical trials ...................................................................................................................... 20
7.7. Planning and reporting ..................................................................................... 20
7.8. Others ............................................................................................................... 20

8. Any other business ................................................................................................. 20
8.1. Demo of the Scientific Explorer tool ................................................................. 20

9. List of participants ............................................................................................... 20
10. Explanatory notes ............................................................................................... 24
1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

The Chairperson opened the meeting by welcoming all participants. The meeting was held remotely.

In accordance with the Agency’s policy on handling of declarations of interests of scientific committees’ members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some Committee members, alternates and experts for concerned agenda topics.

Participants were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared. Restrictions applicable to this meeting are captured in the List of participants included in the minutes.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

The Chair welcomed the new members and alternates and thanked the departing members/alternates for their contributions to the Committee.

The Chair announced the start of the Belgian presidency of the Council of the European Union (EU).

1.2. Adoption of agenda

The CAT agenda for 17-19 January 2024 meeting was adopted.

1.3. Adoption of the minutes

The CAT minutes of 06-09 December 2023 meeting were adopted.

2. Evaluation of ATMPs

2.1. Opinions

No items

2.2. Oral explanations

No items
2.3. **Day 180 list of outstanding issues**

No items

2.4. **Day 120 list of questions**

No items

2.5. **Day 80 assessment reports**

No items

2.6. **Update on ongoing initial applications**

No items

2.7. **New applications**

2.7.1. **Autologous cartilage-derived articular chondrocytes, in-vitro expanded - EMEA/H/C/004594**

TETEC Tissue Engineering Technologies AG; Repair of symptomatic, localised, full-thickness cartilage defects of the knee joint grade III or IV

Scope: Timetable for assessment

**Action:** for adoption

The timetable for assessment was adopted.

2.8. **Withdrawal of initial marketing authorisation application**

No items

2.9. **Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004**

No items

2.10. **Companion diagnostics**

2.10.1. **Initial consultation**

No items

2.10.2. **Follow-up consultation**

No items
2.11. **Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008**

### 2.11.1. Abecma - Idecabtagene vicleucel - Orphan - EMEA/H/C/004662/II/0031

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Rune Kjeken, Co-Rapporteur: Heli Suila, PRAC Rapporteur: Ulla Wändel Liminga

Scope: Clinical, opinion

Extension of indication to include treatment of adult patients with relapsed and refractory multiple myeloma (RRMM) who have received at least two prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD-38 antibody and have demonstrated disease progression on the last therapy for Abecma (idecabtagene vicleucel, ide-cel), based on results from study BB2121-MM-003 (MM-003, KarMMa-3). This is a Phase 3, multicentre, randomised, open-label study to compare the efficacy and safety of ide-cel versus standard regimens in subjects with RRMM. As a consequence, sections 2.1, 2.2, 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2, 6.3, 6.4 and 6.6 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Version 3.0 of the RMP has also been submitted. Furthermore, the product information (PI) is brought in line with the Guideline on core SmPC, Labelling and Package Leaflet for advanced therapy medicinal products (ATMPs) containing genetically modified cells.

**Action:** for adoption


The rapporteur presented the assessment of the responses by the MAH. Based on final assessment, CAT agreed that the benefit risk of Abecma is positive for the extension of indication. CAT discussed the wording of a warning in the SmPC (section 4.4) on the treatment of patients with rapidly progressing disease. CAT agreed with the recommendation for the MAH to submit the final overall survival (OS) data. CAT subsequently discussed what further data could be considered interesting to be collected by the MAH to confirm an optimised bridging therapy.

A positive opinion was adopted by CAT. CAT also concluded that the specific obligation is considered fulfilled, therefore the conditional marketing authorisation (MA) can be converted to a full MA.

### 2.11.2. Alofisel - Darvadstrocel - Orphan - EMEA/H/C/004258/II/0047/G

Takeda Pharma A/S

Rapporteur: Maria Luttgen

Scope: Quality, opinion

**Action:** for adoption

The opinion was adopted.
2.11.3. CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/II/0023

Janssen-Cilag International NV
Rapporteur: Jan Mueller-Berghaus
Scope: Quality
Action: for adoption
Request for supplementary information adopted on 06.10.2023.
The opinion was adopted.

2.11.4. Upstaza - Eladocagene exuparvovec - Orphan - EMEA/H/C/005352/II/0013

PTC Therapeutics International Limited
Rapporteur: Joseph De Courcey
Scope: Quality, request for supplementary information
Action: for adoption
Request for supplementary information adopted on 08.09.2023.
A second request for supplementary information was adopted.

2.11.5. Upstaza - Eladocagene exuparvovec - Orphan - EMEA/H/C/005352/II/0014/G

PTC Therapeutics International Limited
Rapporteur: Joseph De Courcey
Scope: Clinical
Update of sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to update information on safety and efficacy, based on final results from studies NTUH-AADC-010 and NTUH-AADC-011. NTUH-AADC-010 is an open-label, single arm, externally controlled trial to evaluate safety, efficacy, pharmacodynamics and immunogenicity of AGIL-AADC in children from 18 months to less than 18 years of age with severe AADC deficiency, while NTUH-AADC-011 is an open-label, single arm, externally controlled trial to evaluate efficacy and safety of AGIL-AADC in children from 18 months to less than 6 years of age with severe AADC deficiency. In addition, sections 4.5, 4.9 and 6.6 of the SmPC are updated in order to provide better clarification and guidance for the medical practice. The Package Leaflet is updated accordingly. The MAH also took the opportunity to update the due date of the final report of study AADC-1602 in the Annex II, considering the 10-year follow up of the last patient in study AADC-011, and to introduce minor editorial changes to the product information.
Action: for adoption
Request for supplementary information adopted on 06.10.2023.
The opinion was adopted.
2.11.6. **Tecartus; Yescarta - Axicabtagene ciloleucel; Brexucabtagene autoleucel - Orphan - EMEA/H/C/WS2607**

Kite Pharma EU B.V.
Rapporteur: Jan Mueller-Berghaus
Scope: Quality, request for supplementary information

**Action:** for adoption

The request for supplementary information was adopted.

2.11.7. **CARVYKTI - ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/II/0021**

Janssen-Cilag International NV
Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Jo Robays
Scope: Extension of indication, request for supplementary information

Extension of indication to include treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 1 prior therapy, including an immunomodulatory imide drug (IMiDs) and a proteasome inhibitors (PI), have demonstrated disease progression on or after the last therapy and are refractory to lenalidomide for CARVYKTI, based on interim results from study MMY3002 listed as a specific obligation (SOB/006) in the Annex II. This is an ongoing, phase 3, randomised, open-label, multicentre study to determine whether treatment with cilta-cel provides an efficacy benefit compared to standard therapy in participants with relapsed and lenalidomide-refractory multiple myeloma. As a consequence, sections 4.1, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance.

Version 4.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to update Annex II of the product information. As part of the application the MAH is requesting a 1-year extension of the market protection.

**Action:** for discussion (feedback on the ongoing procedure)

Request for supplementary information adopted on 08.09.2023.

CAT requested a reminder of the available data for Carvykti-II-21 in light of a parallel procedure of similar nature.

The Carvykti extension of indication will be discussed at the February 2024 CAT meeting following the assessment of the responses to the request for supplementary information.

2.12. **Extension applications**

No items

2.13. **Other Post-Authorisation Activities**

2.13.1. **Abecma - Idecabtagene vicleucel - Orphan - EMEA/H/C/004662/MEA/007**

Bristol-Myers Squibb Pharma EEIG
Rapporteur: Rune Kjeken
Scope: Pharmacovigilance, opinion

From Initial MAA: Long-term follow-up study (GC-LTFU-001) to assess the risk of delayed adverse events (AEs) following exposure to GM T cells, to monitor for long-term persistence of GM T cells, including analysis of vector integration sites, as appropriate and to monitor for generation of replication competent retroviruses.

**Action:** for adoption

No new safety signals were identified in the first interim report of the study GC-LFTU-001. The conclusion of the report was agreed.

### 2.13.2. Abecma - Idecabtagene vicleucel - Orphan - EMEA/H/C/004662/REC/016.1

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Rune Kjeken

Scope: Quality

**Action:** for adoption

The conclusion of the report was agreed.

### 2.13.3. Breyanzi - Lisocabtagene maraleucel / Lisocabtagene maraleucel - EMEA/H/C/004731/MEA/007

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli

Scope: Pharmacovigilance

From Initial MAA:

LTFU study (GC LTFU 001): Long-term follow-up of safety and efficacy for all paediatric and adult subjects exposed do a GM T cell therapy in Bristol-Myers Squibb sponsored, or Bristol Myers Squibb alliance partner sponsored, clinical trials in accordance with Health Authorities’ guidance for long-term (up to 15 years) follow-up of subjects treated with gene therapy products (interim report 5 year)

**Action:** for adoption

The conclusion of the report and the request for supplementary information were agreed.

### 2.13.4. Breyanzi - Lisocabtagene maraleucel / Lisocabtagene maraleucel - EMEA/H/C/004731/REC/017

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli

Scope: Quality, request for supplementary information

**Action:** for adoption
The conclusion of the report and the request for supplementary information were agreed.

2.13.5. CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/ANX/003.1

Janssen-Cilag International NV
Rapporteur: Jan Mueller-Berghaus
Scope: Pharmacovigilance
PASS STUDY First Interim Report (Study 68284528MMY4004: An observational post-authorization safety study to evaluate the safety of multiple myeloma patients treated with ciltacabtagene autoleucel)
Action: for adoption
The conclusion of the report was agreed.

2.13.6. CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/R/0025

Janssen-Cilag International NV
Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Marcos Timón, PRAC Rapporteur: Jo Robays
Scope: 1-year renewal of marketing authorisation
Action: for adoption
The 1-year renewal of marketing authorisation was adopted.

2.13.7. CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/REC/013.1

Janssen-Cilag International NV
Rapporteur: Jan Mueller-Berghaus
Scope: Clinical
MAH Response to REC 013 [Study MMY2003 Cohort A] Request for supplementary information as adopted in June 2023: safety and efficacy analysis of the subjects who received cilta-cel manufactured with Bern-LV in Study MMY2003 Cohort A.
Action: for adoption
The conclusion of the report was agreed. This recommendation is closed as the scientific issue is part of the variation II/21 for the extension of indication.


Novartis Europharm Limited
Rapporteur: Rune Kjeken
Scope: Pharmacovigilance
MAH's response to ANX 009.6 [Study CCTL019H2301:PAES]: Request for supplementary
information as adopted in October 2023.

**Action:** for adoption

The MAH provided an interim report of study CCTL019H2301 (overall survival data). The conclusion of the report was agreed.

### 2.13.9. Kymriah - Tisagenlecleucel - Orphan - EMEA/H/C/004090/LEG/021.1

Novartis Europharm Limited

Rapporteur: Rune Kjeken

Scope: Pharmacovigilance

MAH's response to LEG 021 [potential secondary malignancy cases including the case number NVS2022DE245136]. Request for supplementary information was adopted in September 2023.

**Action:** for adoption

The conclusion of the report was agreed.

### 2.13.10. Kymriah - Tisagenlecleucel - Orphan - EMEA/H/C/004090/P46/022

Novartis Europharm Limited

Rapporteur: Rune Kjeken

Scope: Clinical

Paediatric studies submitted in accordance with Article 46 of Regulation (EC) No 1901/2006, as amended. Final study report NO. CCTL019C2202: a phase II, single arm, multicentre open label trial to determine the safety and efficacy of tisagenlecleucel in paediatric patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma (NHL) (BIANCA)

**Action:** for adoption

The conclusion of the report was agreed. The product information is unchanged.

### 2.13.11. Luxturna - Voretigene neparvovec - Orphan - EMEA/H/C/004451/REC/012

Novartis Europharm Limited

Rapporteur: Sol Ruiz

Scope: Quality

**Action:** for adoption

The conclusion of the report was agreed.

### 2.13.12. ROCTAVIAN - Valoctocogene roxaparvovec - Orphan - EMEA/H/C/005830/SOB/006

BioMarin International Limited

Rapporteur: Violaine Closson Carella
Scope: Clinical, pharmacovigilance

Study 270-303 1-Year CSR: a phase 3b, single arm, open-label study to evaluate the efficacy and safety of BMN 270, an adeno-associated virus vector–mediated gene transfer of human factor VIII, with prophylactic corticosteroids in haemophilia A patients.

**Action:** for adoption

The conclusion of the report was agreed.

2.13.13. **Abecma - idecabtagene vicleucel; Breyanzi - lisocabtagene maraleucel; Carvykti - ciltabtagene autoleucel; Kymriah - tisagenlecleucel; Tecartus - brexucabtagene autoleucel; Yescarta - axicabtagene ciloleucel**

Bristol-Myers Squibb Pharma EEIG (Abecma, Breyanzi), Janssen-Cilag International NV (Carvykti), Novartis Europharm Limited (Kymriah), Kite Pharma EU B.V. (Tecartus, Yescarta)

CAT Rapporteurs: Rune Kjeken (Kymriah, Abecma), Jan Mueller-Berghaus (Carvykti, Tecartus, Yescarta), Concetta Quintarelli (Breyanzi)

PRAC Rapporteur (for the signal): Ulla Wändel Liminga

Scope: Feedback from PRAC discussion on signal of secondary malignancies of T-cell origin (EPITT 20040)

**Action:** for information

CAT was informed about the PRAC discussion on the signal of secondary malignancies of T-cell origin. The signal is under review and is scheduled for further PRAC discussion in April 2024. CAT will be informed of the outcome of the PRAC discussion.

2.14. **GMP and GCP inspections requests**

No items

3. **Certification of ATMPs**

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. **Opinion**

No items

3.2. **Day 60 Evaluation Reports**

No items

3.3. **New Applications**

No items
4. Scientific Recommendation on Classification of ATMPs

Timetable:
- Start of the procedure: 19.01.2024
- EMA Coordinator’s draft report: 02.02.2024
- CAT Coordinator’s comments: 07.02.2024
- Revised scientific recommendation: 09.02.2024
- CAT’s discussion of scientific recommendation: 16.02.2024

4.1. New requests – Appointment of CAT Coordinator

4.1.1. Modified measles vaccine virus

For the treatment of solid cancer tumours
Scope: Appointment of CAT Coordinator and adoption of timetable

**Action:** for adoption

The CAT coordinator was appointed.

4.2. Day 30 ATMP scientific recommendation

4.2.1. Allogeneic expanded natural killer cells

For the treatment of acute myeloid leukaemia
Scope: ATMP scientific recommendation

**Action:** for adoption

CAT discussed the classification report.

4.2.2. Autologous tissue generated in the human body (in vivo) through the foreign body reaction

For tissue augmentation
Scope: ATMP scientific recommendation

**Action:** for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 02.02.2024.

4.2.3. Dendritic cells activated by lysate of circulating tumour cells

For the treatment of solid tumours in metastatic stage
Scope: ATMP scientific recommendation

**Action:** for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific
recommendation to the European Commission for comments by 02.02.2024.

4.2.4. **Autologous T Lymphocytes engineered with nanoparticles with curcumin encapsulated**

For the treatment of melanoma

Scope: ATMP scientific recommendation

**Action:** for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 02.02.2024.

4.3. **Day 60 revised scientific recommendation (following list of questions)**

4.3.1. **Spermatogonial stem cells, propagated in vitro**

Male infertility due to gonadotoxic treatment

Scope: ATMP scientific recommendation

**Action:** for adoption

The CAT coordinator presented the updated classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 02.02.2024.

CAT was informed of scientific developments specifically in the field of infertility treatments: reference was made to national scientific advice requests. The developer should be recommended to come for ATMP classification early on to confirm the regulatory framework for its product.

4.4. **Finalisation of procedure**

4.4.1. **Allogeneic peripheral blood-derived HSPC, Treg cells and Tcon cells**

Prevention of moderate to severe chronic graft-vs.-host disease and/or death in patients with acute leukaemias and in patients with myelodysplastic syndrome (MDS) undergoing HLA-matched allogeneic haematopoietic stem cell transplant (alloHCT)

Scope: European Commission raised no comments. ATMP scientific recommendation

**Action:** for adoption

The classification report was adopted. The product does not fulfil the definition of an advanced therapy medicinal product as provided in Article 2(1) of Regulation (EC) No. 1394/2007.

4.5. **Follow-up and guidance**

No items
5. **Scientific Advice**

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. **New requests - appointment of CAT Rapporteurs**

5.1.1. **Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers**

**Timetable:**

- Start of procedure at SAWP: 08-11.01-2024
- Appointment of CAT Peer Reviewers: 17-19.01.2024
- SAWP first reports: 29.01.2024
- CAT Peer Reviewer comments (NC/C): 02.02.2024
- CAT Peer Reviewer comments (Q): 07.02.2024
- Discussion at SAWP: 05-08-02.2024
- Discussion at CAT and feedback to SAWP: 14-16.02.2024

5.1.2. **Scientific advice procedures starting at the next SAWP meeting**

**Timetable:**

- Start of procedure at SAWP: 05-08.02.2024
- Appointment of CAT Peer Reviewers: 14-16.02.2024
- SAWP first reports: 26.02.2024
- CAT Peer Reviewer comments (NC/C): 01.03.2024
- CAT Peer Reviewer comments (Q): 06.02.2024
- Discussion at SAWP: 04-07.03.2024
- Discussion at CAT and feedback to SAWP: 13-15.03.2024

5.2. **Procedures discussed at SAWP – 1st reports, D40 JRIs, LoIs**

5.3. **Finalisation of D70 procedures – feedback from the discussion meeting**

5.4. **Final Advice Letters for procedures finalised the previous month**

6. **Pre-Authorisation Activities**

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. **Paediatric investigation plans**

No items
6.2. ITF briefing meetings in the field of ATMPs

6.3. Priority Medicines (PRIME) – Eligibility requests

6.3.1. Month 0 - Start of the procedure

Timetable for assessment:
- Procedure start: 08-11.01.2024
- SAWP recommendation: 08.02.2024
- CAT recommendation: 16.02.2024
- CHMP adoption of report and final recommendation: 22.02.2024

6.3.2. Month 1 – Discussion of eligibility

6.3.3. Month 2 – Recommendation of eligibility

6.3.4. Ongoing support

No items

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. CAT membership

**Action:** for information

The CAT Chair welcomed Anna Katalin Barane Gilicse and Viola Bardczy as the new member and alternate for Hungary and thanked Balázs Sarkadi for his contribution as the alternate for Hungary.

The CAT Chair welcomed Joseph De Courcey and Richard Carroll as the new member and alternate for Ireland and thanked Maura O’Donovan and Niamh Curran for their contribution as member and alternate for Ireland.

The CAT Chair welcomed Vilma Petrikaite as the new member for Lithuania.

The CAT Chair welcomed Alessia Pochesci and Nancy De Bremaeker as the new member and alternate for Luxembourg and thanked Guy Berchem for his contribution as alternate for Luxembourg.
7.1.2. **Vote by proxy**

**Action:** for information

None

7.1.3. **CAT Strategic Review & Learning meeting (SRLM) under the Belgian presidency – 15-17 May 2024**

CAT: Claire Beuneu

Scope: Draft agenda of the upcoming SRLM

**Action:** for discussion

A first discussion took place on the agenda of the CAT-only meeting and the joint CAT-PDCO meeting during the upcoming SRLM.

7.2. **Coordination with EMA Scientific Committees**

7.2.1. **BWP/CAT training on AAV based gene therapy**

Scope: Discussion on upcoming training on AAV based gene therapy

Coordinator: Sean Barry, Ilona Reischl

**Action:** for information

CAT was informed on the planned training on quality requirements for AAV based gene therapy products.

7.2.2. **Update on revamp project: available new templates, ongoing template revision and industry pilot**

Scope: Provide update to the CAT members of the ongoing project and the achievements reached to this point

**Action:** for information

CAT was informed on the second phase of the Revamp project on revision of Initial Marketing Authorisation templates for assessment. A pilot project with industry has started whereby selected applicants on a voluntary basis will include factual data in the D80 clinical/non-clinical assessment reports. ATMPs have not been selected so far for this pilot but will be included for consideration from now on if criteria used for the pilot industry involvement are being satisfied. As an incentive, the involved companies will have more dedicated interactions with the rapporteurs and assessors, which would allow for simple issues (such clarification or mistakes in the dossier, or the provision of missing documents) to be resolved without the need for committee involvement: this should give the opportunity to reduce the number of questions and the time for assessment.

7.3. **Coordination with EMA Working Parties/Working Groups/Drafting Groups**

No items
7.4. **Cooperation with the EU regulatory network**

No items

7.5. **Cooperation with international regulators**

No items

7.6. **CAT work plan**

7.6.1. **CAT work plan for 2024**

CAT: Ilona Reischl

Scope: Draft CAT work plan for 2024

**Action:** for discussion

The CAT work plan for 2024 was adopted and will now be published on the EMA website. The activity related to the SMA registry study (see agenda point 7.6.2) was removed from the 2024 work plan.

7.6.2. **Update on real-world evidence (RWE) studies to support EMA scientific committees**

Scope: Outcome of the SMA registry study

**Action:** for information

CAT received detailed feedback on the outcome of the Spinal muscular atrophy (SMA) registry study. CAT was informed that the final report is being finalised and a manuscript is under preparation. No additional activities involving CAT are planned on this SMA registry study.

7.6.3. **Reflection paper on the use of real-world data to generate real-world evidence in non-interventional studies**

CAT: Ilona Reischl, Rozalina Kuloksozova

Scope: Comment from CAT on the draft Reflection Paper on real-world evidence

**Action:** for discussion

Rozalina Kuloksozova and Ilona Reischl informed CAT of their observations on the above mentioned reflection paper. The main concern is that less experienced applicants might misunderstand or misuse the reflection paper to replace clinical trial data by real-world evidence data obtained from non-interventional studies. It is proposed that the reflection paper includes cautionary statements in this respect.

EMA thanked the CAT members for the careful review and comments provided. The comments will be addressed in due course by the drafting group. Concerning the main point described above, EMA mentioned that, while the reflection paper already includes statements to make clear that real-world evidence is to complement and not to replace
evidence from clinical trials, the drafting group will consider emphasising that message to mitigate the risk of misinterpretation or misuse of the reflection paper by sponsors.

**7.6.4. Guideline on quality, non-clinical and clinical requirements for investigational ATMPs in clinical trials**

CAT: Ilona Reischl
Scope: Draft guideline, updated following the external consultation
Action: for discussion

CAT was informed that the comments from the external consultation have now been reviewed and incorporated in the guideline where relevant. CAT members are invited to review the updated guideline and provide comments by 9 February 2024. The guideline will be adopted at the February 2024 CAT meeting. In view of the many changes to the guideline text (especially to the quality part), a short second public consultation is scheduled.

**7.7. Planning and reporting**

No items

**7.8. Others**

No items

**8. Any other business**

**8.1. Demo of the Scientific Explorer tool**

Scope: AI/Knowledge Mining driven tool that EMA is developing to allow easy and accurate searching, finding, interrogating and accessing of scientific information to inform scientific decisions. The scope of the tool’s first version are scientific advice letters.

Action: for information

A demonstration of the search engine that is under development for data mining in scientific advice letters was given. The tool will become available later this year.

Date of next CAT meeting:

14-16 February 2024

**9. List of participants**

Including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 16-19 January 2024 meeting.
<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>State or affiliation</th>
<th>Outcome restriction following evaluation of e-DoI</th>
<th>Topics on agenda for which restrictions apply</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ilona Reischl</td>
<td>Chair</td>
<td>Austria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Silke Dorner</td>
<td>Member</td>
<td>Austria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Claire Beuneu</td>
<td>Member</td>
<td>Belgium</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Olga Kholmanskikh</td>
<td>Alternate</td>
<td>Belgium</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Rozalina Kulaksazova</td>
<td>Member</td>
<td>Bulgaria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Azra Selimovic</td>
<td>Member</td>
<td>Croatia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Petra Sokol</td>
<td>Alternate</td>
<td>Croatia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Rafaella Pontou</td>
<td>Member</td>
<td>Cyprus</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Isavella Kyriakidou</td>
<td>Alternate</td>
<td>Cyprus</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Petr Soukup</td>
<td>Member</td>
<td>Czechia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Ebru Karakoc Madsen</td>
<td>Member</td>
<td>Denmark</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Bibi Fatima Syed Shah</td>
<td>Alternate</td>
<td>Denmark</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Toivo Maimets</td>
<td>Member</td>
<td>Estonia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Pille Saalik</td>
<td>Alternate</td>
<td>Estonia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Heli Suila</td>
<td>Member</td>
<td>Finland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Maija Tarkkanen</td>
<td>Alternate</td>
<td>Finland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Violaine Closson Carella</td>
<td>Member</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Jean-Michel Race</td>
<td>Alternate</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Jan Mueller-Berghaus</td>
<td>Member (CHMP co-opted member)</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Egbert Flory</td>
<td>Alternate (to CHMP representative)</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Maria Gazouli</td>
<td>Member</td>
<td>Greece</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Angeliki Rompoti</td>
<td>Alternate</td>
<td>Greece</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Anna Katalin Barane Glicize</td>
<td>Member</td>
<td>Hungary</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Member State or affiliation</td>
<td>Outcome restriction following evaluation of e-DoI</td>
<td>Topics on agenda for which restrictions apply</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------------------------------------------</td>
<td>-----------------------------</td>
<td>---------------------------------------------------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>Viola Bardoczy</td>
<td>Alternate</td>
<td>Hungary</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Joseph De Courcey</td>
<td>Member</td>
<td>Ireland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Concetta Quintarelli</td>
<td>Member</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Una Riekstina</td>
<td>Member</td>
<td>Latvia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Villma Perikaite</td>
<td>Member (CHMP member)</td>
<td>Lithuania</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Raimondas Benetis</td>
<td>Alternate (to CHMP representative)</td>
<td>Lithuania</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Nancy De Bremaeker</td>
<td>Alternate</td>
<td>Luxembourg</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Anthony Samuel</td>
<td>Alternate (to CHMP representative)</td>
<td>Malta</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Emmely de Vries</td>
<td>Member</td>
<td>Netherlands</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Berendina Maria (Tineke) van den Hoorn</td>
<td>Alternate</td>
<td>Netherlands</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Rune Kjeken</td>
<td>Member</td>
<td>Norway</td>
<td>No participation in discussion, final deliberations and voting on: Bizalimogene ralaplasmid, mavilimogene ralaplasmid</td>
<td></td>
</tr>
<tr>
<td>Dariusz Sladowski</td>
<td>Member</td>
<td>Poland</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Maria Isabel Borba Vieira</td>
<td>Alternate (to CHMP representative)</td>
<td>Portugal</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Silviu Istrate</td>
<td>Member</td>
<td>Romania</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Katarina Kollarova</td>
<td>Member</td>
<td>Slovakia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Margareta Fogelová</td>
<td>Alternate</td>
<td>Slovakia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Metoda Lipnik-Stangelj</td>
<td>Member</td>
<td>Slovenia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Suzana Vidic</td>
<td>Alternate</td>
<td>Slovenia</td>
<td>No participation in final deliberations and voting on: 2.13.8, 2.13.9; 2.13.10 Kymriah 2.13.11 Luxturna</td>
<td></td>
</tr>
<tr>
<td>Sol Ruiz</td>
<td>Member (CHMP co-opted member)</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Member State or affiliation</td>
<td>Outcome restriction following evaluation of e-DoI</td>
<td>Topics on agenda for which restrictions apply</td>
</tr>
<tr>
<td>---------------------------</td>
<td>-------------------------------------</td>
<td>----------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Marcos Timón</td>
<td>Alternate (to CHMP representative)</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Maria Luttgen</td>
<td>Member</td>
<td>Sweden</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Charlotte Anderberg</td>
<td>Alternate</td>
<td>Sweden</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Paolo Gasparini</td>
<td>Member</td>
<td>Clinicians' Representative</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Alessandra Renieri</td>
<td>Alternate</td>
<td>Clinicians' Representative</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Kerstin Sollerbrant Melefors</td>
<td>Member</td>
<td>Patients' Representative</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Mencia de Lemus Belmont</td>
<td>Alternate</td>
<td>Patients' Representative</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Kieran Breen</td>
<td>Member (Vice-Chair)</td>
<td>Patients' Representative</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Federica Chiara</td>
<td>Alternate</td>
<td>Patients' Representative</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Torjorn Callreus</td>
<td>Expert</td>
<td>Malta</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Lothar Bergmann</td>
<td>Expert</td>
<td>Germany</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lena Eroukhmanoff</td>
<td>Expert</td>
<td>Norway</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Fabrice Eroukhmanoff</td>
<td>Expert</td>
<td>Norway</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Nina Pettersen Hessvik</td>
<td>Expert</td>
<td>Norway</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Ingrid Wang</td>
<td>Expert</td>
<td>Norway</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Ulla Wändel Liminga</td>
<td>Expert</td>
<td>Sweden</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Beate Mosl</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Attila Sebe</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Karri Penttilä</td>
<td>Expert</td>
<td>Finland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Johanna Lähteenvuuo</td>
<td>Expert</td>
<td>Finland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Odoardo Maria Olimpieri</td>
<td>Expert</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Antonella Isgro</td>
<td>Expert</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
</tbody>
</table>
### Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

For a list of acronyms and abbreviations, see:

[List of abbreviations used in EMA human medicines scientific committees and CMDh documents, and in relation to EMA’s regulatory activities](#)

**Evaluation of ATMPs (section 2)**

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists Post-authorisation activities (section 2.11-2.13) and any ATMP related inspection requests (section 2.14).

**New applications (sections 2.1. to 2.9.)**

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found [here](#).

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:

![Diagram of ATMP evaluation process]

The assessment of an application for a new medicine takes up to 210 ‘active’ days. This active evaluation time is interrupted by at least one ‘clock-stop’ during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.4) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (Ongoing evaluation procedures) (section 2.3). Section 2.6 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.
**Oral explanation (section 2.2.)**

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

**New applications (section 2.7.)**

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

**Withdrawal of applications (section 2.8.)**

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

**Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.9.)**

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

**Companion diagnostics (section 2.10)**

This section lists applications for initial and follow-on consultation of companion diagnostics.

**Post-authorisation activities (section 2.11-2.13.)**

Section 2.11 lists type II variations, including extension of indication applications and re-examination procedures for type II variations for which the applicant has requested re-examination of the opinion previously issued by the CHMP. Section 2.12 list extension application according to Annex I of Reg. 1234/2008 and section 2.13 includes all other post-authorisation activities concerning authorised ATMPs that are not covered elsewhere in the agenda such as post-authorisation measures, annual reassessments, 5-year renewals, supply shortages, quality defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA’s committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

**GMP and GCP Inspections Issues (section 2.14.)**

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

**Certification of ATMPs (section 3)**

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found [here](#).

**Scientific Recommendation on Classification of ATMPs (Section 4)**

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found [here](#).
Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found here.

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found here.

Priority Medicines (PRIME)

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/